Lexicon Pharmaceuticals (NASDAQ:LXRX) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research report report published on Thursday, Benzinga reports. HC Wainwright currently has a $10.00 price target on the biopharmaceutical company’s stock.

Separately, StockNews.com raised Lexicon Pharmaceuticals to a “sell” rating in a research report on Tuesday, July 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $7.50.

Lexicon Pharmaceuticals Trading Up 5.2 %

NASDAQ LXRX opened at $2.01 on Thursday. The stock has a market cap of $494.94 million, a P/E ratio of -2.42 and a beta of 1.28. Lexicon Pharmaceuticals has a fifty-two week low of $0.92 and a fifty-two week high of $3.73. The stock has a 50 day simple moving average of $1.68 and a two-hundred day simple moving average of $1.78. The company has a debt-to-equity ratio of 0.41, a quick ratio of 11.49 and a current ratio of 11.51.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.01. Lexicon Pharmaceuticals had a negative net margin of 5,509.34% and a negative return on equity of 105.38%. The business had revenue of $1.65 million for the quarter, compared to analysts’ expectations of $2.74 million. During the same quarter in the previous year, the business posted ($0.22) earnings per share. On average, analysts forecast that Lexicon Pharmaceuticals will post -0.69 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. CVI Holdings LLC bought a new position in shares of Lexicon Pharmaceuticals during the second quarter valued at approximately $34,000. Principal Financial Group Inc. increased its position in Lexicon Pharmaceuticals by 116.1% during the 2nd quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 12,225 shares in the last quarter. Great Point Partners LLC purchased a new position in Lexicon Pharmaceuticals during the second quarter valued at $50,000. Virtu Financial LLC bought a new stake in Lexicon Pharmaceuticals in the first quarter worth $105,000. Finally, Victory Capital Management Inc. grew its stake in shares of Lexicon Pharmaceuticals by 44.5% in the second quarter. Victory Capital Management Inc. now owns 45,341 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 13,972 shares during the last quarter. 74.70% of the stock is owned by hedge funds and other institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.